This LFA can be considered an open source design for an antigen-detecting point of care test for SARS-CoV-2, as it is designed entirely from commercially available materials. If antibody supplies for the antibodies chosen herein are limited, our previously reported antibody screening effort can be utilized to select alternate choices. The information we present could be used by any organization to develop an LFA for both validation or towards largescale production. This first-generation product can likely benefit from further optimization and improved performance through higher sensitivity nanoparticles, etc. This test was designed with a buffer compatible with anterior nares swabs. Future work should confirm its suitability in other sample matrices, including saliva.